New Studies
2007 - 2005
Older Studies
Pre 1990

What is It
Does it Work
Is it Safe
Good Earth Medicine

Arbidol research index:

Journal of Pharmaceutical and Biomedical Analysis 2006, Article In Press English publication .pdf

Determination of arbidol in human plasma by LC-ESI-MS

Xiao Lui, Yu-Wei Huang, Juan Li, Xiao-Bo Li, Kai-Shun Bi, Xiao-Hui Chen

A sensitive, specific and accurate method for determination of arbidol in human plasma was developed. Arbidol and internal standard were extracted from plasma samples by liquid-liquid extraction with diethyl ether. The chromatographic separation was accomplished on a Shiseido C 18 3 pm.m analytical column (100 mm x 2.0 mm i.d.) at a flow rate of 0.3 mL/min isocratically. Detection was performed on a single quadrupole mass spectrometer by selected ion monitoring (SIM) mode via electrospray ionization (ESI) source. The method had a chromatographic run time of 6 min. and a good linear relationship over the range 1-1000 ng/mL. The limit of quantitation for arbidol in plasma was 1 ng/mL. The intra-day and inter-day precision (R.S.D. %) was lower than 7% and accuracy ranged from 96-105%. The proposed method enables unambiguous identification and quantification of arbidol in vivo and has been successfully applied to study the pharmacokinetics of arbidol in heathy male Chinese volunteers.

Chinese Journal of Pharmaceutics 2006 6 Full text not available at this time

Arbidol hydrochloride sustained-release pellets Preparation and Evaluation of in vitro release

Woodland generation, Li Ming, Yu Li, Dan Yin, Hui-Min Yao

Shenyang Pharmaceutical University College of Pharmacy, Shenyang, Liaoning 11001

Abstract : Objective Arbidol hydrochloride sustained-release pellets and studied in vitro release of the influencing factors. Core prescription pill containing orthogonal design optimization method, the single factor inspection coating liquid plasticizer, anti-adherent. Hole detergent coating weight to the impact of drug release. Results for the MCC and lactose pills core adjuvants to EUDRAGIT 1219 RL30D of hydrophobic material, the mass fraction of liquid coating 20, TEC mass fraction of 15% mass fraction of 50% talc, lactose content of 5% to 20% weight coating better release can be obtained at the sustained-release pellets.

Conclusion Arbidol hydrochloride sustained-release pellets in vitro obvious sustained release characteristics Release level with the release model.

Chinese Journal of Pharmaceutics 2006 6 Full text not available at this time

Arbidol hydrochloride sustained-release pellets Preparation and Evaluation of in vitro release

DAI Yi, LI San-ming, YU Li-min, Dan name, YAO Hui-min

School of Pharmacy. Shenyang Pharmaceutical University, Shenyang 110016, China

Abstract : Objective To prepare arbidol hydrochloride sustained-release pellets and investigate the mechanism of release. Methods The orthogonal design was used to optimize the formulation of the core of pellets. Single-method was used to investigate the influence of contenting of plasticizer. anti-adherent, poremaking agent, coating levels on the release of the pellets. Results The core of pellets were prepared by MCC and lactose. with EUDRAGIT 1219 RL30D as coating materials. The gained weight of the coated pellets was 20%.

Conclusions The coated sustained-release pellets has a remarkable property. the drug release profile in vitro follows first order kinetics.

Zh Mikrobiol Epidemiol Immunobiol. 2005 Nov-Dec;(6): 24-8. English (professional translation .html)

Characteristics of the immune status in specific and nonspecific prophylaxis of influenza in elderly persons, March 2005

T. A. Semenenko, E. P. Seikova, T. P. Gotvyanskaya, A. D. Gaidarenko, N. A. Polezhaeva, L. F. Evseeva, O. G. Nikolaeva

The results of the comparative analysis of the immunological effectiveness of the anti-influenza vaccine Vaxigrip, the interferon inductor arbidol and their combination in 125 elderly persons are presented. In the process of investigation, the immunomodulating activity of the preparations under study was noted. This activity was manifested by the increase of the absolute and relative number of cells carrying CD3+, CD4+ and CD16+ markers, but not CD8+, CD19+ or CD25+; normalization of the immunoregulatory index and stimulation of phagocytic function without significant influence on the level of HLA-DR+ expression or on the concentration of the main classes of immunoglobulins. An increase in the frequency of seroconversions and the multiplicity of growth in the titers of specific antibodies to influenza viruses A (H1N1 and H3N2) and B, most pronounced in persons given arbidol along with an anti-influenza vaccine, was established.

PMID: 16438370 [PubMed - in process]

Original Russian Document .pdf

Modern Chinese Pharmaceutical Applications, 2005 period z3 Full text not available at this time

Synthesis of Arbidol hydrochloride

Er, Yan-Fang Zhao, Gong Ping, SONG Yan-ling, ZHAO Yan-fang, GONG Ping

Objective To introduce a new method of synthesis of Arbidol hydrochloride. Methods chlorinated through ? ? ethyl acetoacetate as the starting material. Amine, Nenitzescu reaction Mannich reaction of acetylation protection bromide and protective, A total of eight-step reaction of salt Arbidol hydrochloride. TLC set by the end of each step reaction. Results infrared structure, NMR and MS. total yield of 11.2%. Conclusion This method is feasible.

Chinese Journal of Medicinal Chemistry 2004 04 Full text not available at this time

Synthesis and anti-influenza virus activity of ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylate

Objective Design and Synthesis of 5-hydroxy-1H - indole-3-carboxylate ethyl ester compounds. evaluation of its anti-virus and anti-respiratory syncytial virus activity. Methods IR, 1H - NMR and MS object structure, In vitro anti-HIV activity and screening tests. The results and conclusion of the nine 5-hydroxy-1H - indole-3-carboxylate ethyl ester compounds. Initial activity showed that the inhibition of influenza virus and certain respiratory syncytial virus, which compounds VIII 1. ? 2, 5 VIII of the antiviral activity of ribavirin and Arbidol with considerable.

Journal of Shenyang Pharmaceutical University, 2004 02 period Full text not available at this time

Research on the action mutations induced by arbidol - Api mutagenic effect of indomethacin

Zheng Yu Yang, Li Lili, Zhang Xiuli

Objective Api ? mutagenesis. Methods microbial mutagenicity test mouse micronucleus test. Mammalian cell culture chromosome test The observation echoes of indomethacin on cell mutagenicity. Effects of the Ames test results Api, the micronucleus test in mice. CHL cell chromosome aberration test results were negative, no mutagenic Api indomethacin. Conclusion arbidol no mutagenic effect.

RMZH,Volume 11 No. 12 2002 English (babblefish .html)

The molecular-biological special features of the action of Arbidol the new antiviral preparation

Arbidol, the new antiviral preparation, effective with respect to the viruses of influenza A and B. the Molecular- biological special features of the action of Arbidol are determined by its ability to suppress the reproduction of virus at the early stages, the action of preparation realizes with a change in the regulation of cellular metabolism. Preparation is differed from remantadine in the molecular mechanism of antiviral action.

Vestn Ross Akad Med Nauk. 1999;(3):36-40. - Full text not available at this time

Mechanisms of arbidole's immunomodulating action

Glushkov RG, Gus'kova TA, Krylova LIu, Nikolaeva IS.

The immunomodulating activity of arbidole was studied in cultured cells, animals, and human beings. Arbidole was shown to have effects on nonspecific defense factors, on its capacity to induce interferon and activate phagocytes in particular. Arbidole-treated patients with lower baseline immunity showed improvement in immunological parameters (in the counts of CD4 and CD8 lymphocytes, B lymphocytes, in the levels of serum immunoglobulins). Arbidol produces a high preventive and therapeutical effects in influenza A and B and other acute respiratory viral infections, prevents postinfluenza complications, reduces the incidence of exacerbations of chronic diseases in postinfluenza patients. In influenza, the therapeutical efficiency of the drug appears as decreases in intoxication, the severity of catarrhal syndrome, shorter fever and disease in general. Arbidole is beneficial for patients with second immunodeficiency, in those with recurrent herpes infection or chronic bronchitis. After arbidole treatment regimen, postoperative immunological parameters became normal in cardiac surgical patients, which suggests that the drug should be used in cardiac surgical care. The agent showed no side effects in any case.

PMID: 10222830 [PubMed - indexed for MEDLINE]

J Chromatogr A. 1998 Jun 12;810(1-2):63-9. English publication .pdf

Sensitive high-performance liquid chromatographic determination of arbidol, a new antiviral compound, in human plasma.

Metz R, Muth P, Ferger M, Kukes VG, Vergin H.

Heumann Pharma, Nurnberg, Germany.

A highly sensitive and selective HPLC method was developed and validated for the determination of arbidol in human plasma. The method involves the liquid-liquid extraction of drug and internal standard from plasma with tert.-butyl methyl ether followed by evaporation and reconstitution in mobile phase. UV detection was done at 315 nm. The limit of quantification for arbidol in plasma was 0.005 microgram/ml. Linearity in plasma was proven over the whole calibration range (10.2-0.005 micrograms/ml). The method was validated according to GLP guidelines and its suitability was demonstrated by analysis of samples from a pharmacokinetic study.

PMID: 9691291 [PubMed - indexed for MEDLINE]

Radiats Biol Radioecol. 1994 Jul-Oct;34(4-5):482-8. - Full text not available at this time

Immunopharmacological analysis of secondary postradiation immunodeficiency

Ivanov AA, Deshevoi IuB, Karpova NA, Lebedev VG, Leonenko IV, Stavrakova NM, Tazulakhova EB, Ulanova AM, Khaustova LI, Shal'nova GA, et al.

A model for secondary postradiation immunodeficiency of mice has been used to compare immunocorrective activities of some new immunomodulators (arbidol, cagocel, myelopid, proleukinferon and fragmine) administered at late times (2-3 months) after exposure to a nonlethal radiation dose (4.0 Gy). The highest immunocorrective effect has been shown with fragmine and proleukinferon.

PMID: 7951873 [PubMed - indexed for MEDLINE]

is a website set up to provide the English speaking world information about the antiviral medicine Arbidol.

Statements, claims, and comments on this web site related to Aribidol are derived from published studies regarding the drug, and are merely the interpretations and summaries by of its understanding of those studies. The reader is encouraged to review the studies themselves and to form their own interpretation.

Comments Form

© 2009 Good Earth Medicine LLC.